1615 related articles for article (PubMed ID: 27455225)
1. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
2. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
3. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
Garg M
Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer stem cells: emerging target for designing novel therapy.
Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.
Du F; Liu H; Lu Y; Zhao X; Fan D
Crit Rev Oncog; 2017; 22(3-4):275-282. PubMed ID: 29604904
[TBL] [Abstract][Full Text] [Related]
6. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
Mitra A; Mishra L; Li S
Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
[TBL] [Abstract][Full Text] [Related]
7. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.
Katsuno Y; Meyer DS; Zhang Z; Shokat KM; Akhurst RJ; Miyazono K; Derynck R
Sci Signal; 2019 Feb; 12(570):. PubMed ID: 30808819
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cell (CSC) resistance drivers.
Najafi M; Mortezaee K; Majidpoor J
Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
[TBL] [Abstract][Full Text] [Related]
9. Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis.
Iqbal W; Alkarim S; AlHejin A; Mukhtar H; Saini KS
Oncotarget; 2016 Nov; 7(46):76337-76353. PubMed ID: 27486983
[TBL] [Abstract][Full Text] [Related]
10. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
[TBL] [Abstract][Full Text] [Related]
11. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights.
Li H; Batth IS; Qu X; Xu L; Song N; Wang R; Liu Y
Mol Cancer; 2017 Jan; 16(1):6. PubMed ID: 28137302
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
13. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of epithelial-mesenchymal transition and cancer stem cells.
Topcul M; Cetin I
J BUON; 2016; 21(2):312-9. PubMed ID: 27273939
[TBL] [Abstract][Full Text] [Related]
15. Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.
Ramesh V; Brabletz T; Ceppi P
Trends Cancer; 2020 Nov; 6(11):942-950. PubMed ID: 32680650
[TBL] [Abstract][Full Text] [Related]
16. Roles of epithelial-mesenchymal transition in cancer drug resistance.
Shang Y; Cai X; Fan D
Curr Cancer Drug Targets; 2013 Nov; 13(9):915-29. PubMed ID: 24168191
[TBL] [Abstract][Full Text] [Related]
17. The bad seed: Cancer stem cells in tumor development and resistance.
Koren E; Fuchs Y
Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
[TBL] [Abstract][Full Text] [Related]
18. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
19. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
20. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer.
Zhou P; Li B; Liu F; Zhang M; Wang Q; Liu Y; Yao Y; Li D
Mol Cancer; 2017 Feb; 16(1):52. PubMed ID: 28245823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
